The Siemens cystatin C immunoassay has been widely used in clinical research, particularly in the US. In recent years, however, the results obtained with the method appear to have changed.
The glomerular filtration rate (GFR) is generally accepted as the best overall indicator of kidney function and is an important measure for assessing kidney disease. Several studies have shown cystatin C to be superior to creatinine for estimation of the GFR (1 ), which is usually expressed as the relative GFR [in units of mL ⅐ min
]. This practice has led to the development of formulas to convert cystatin C measurements in milligrams per liter to a calculated GFR in these units, without the need for demographic coefficients (2, 3 ) . The formulas were developed from studies that compared cystatin C concentrations with measured GFRs by using such exogenous markers as iohexol, diethylenetriamine pentaacetic acid or 51 Cr-EDTA clearance (4 ) .
We were concerned that the calibration of the Siemens cystatin C method had changed during the last 5 years, because we noted that thecystatinCconcentrationsofparticipants in a longitudinal cohort improved substantially over time. The study investigators considered these results implausible because the GFR is known to decrease with age. The aim of the present study was to determine whether the Siemens cystatin C method has changed its calibration during the last 5 years and, if so, to quantify the magnitude of the change.
We used our laboratory's current routine method from Gentian as a comparative method. To ensure that the comparative method had been stable, we verified that each lot of the Gentian reagent produced results within 3% of the originally assigned values for 10 patient serum pools prepared in 2005 and stored at Ϫ70°C. Freshly collected and lithium heparintreated samples obtained from routine cystatin C requests were then used to compare the 2 cystatin C methods. New sets of patient samples were used for each comparison between 2006 and 2010 (Table 1) .
Plasma cystatin C was analyzed on an Architect ci8200 analyzer (Abbott Diagnostics) with reagents and calibrator from Gentian and on a BN ProSpec analyzer (Siemens Healthcare Diagnostics) with reagents and calibrator from Siemens.
A Deming regression analysis showed no significant difference between the 2 methods in 2006 (Table 1) the estimated GFR, the bias in cystatin C concentrations in patients with a normal kidney function and those with a moderately decreased kidney function had the greatest effect on the estimated GFR. Therefore, it is essential that the calibration of the cystatin C method be consistent, because small changes in cystatin C will introduce a large bias in GFR estimates. 
